CNS - Cohen & Steers, Inc. 0 WATCHERS

RVPH Might Be the Sleeper Play Nobody’s Talking About Not financial advice — just what I’m seeing. RVPH has been way too quiet for a stock sitting this close to an FDA submission. Most under-$1 biotechs are pre-clinical junk. This one actually finished Phase 3 with solid safety and promising …

BDTX Phase 2 update shorts in trouble upvote post. Black Diamond Therapeutics (BDTX) just released preliminary Phase 2 data for silevertinib in 1L NSCLC — and it's way stronger than expected: 🔥 Clinical Results (Headline Numbers) 60% ORR across 35 different non-classical EGFR mutations 86% CNS response rate (brain mets) …

Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …

Alpha Cognition (ACOG: Nasdaq) Undervaluation Thesis -A $6 Stock (EV: $57M) That's Being Valued on Trailing Revs Instead of 2026 Reality Alpha Cognition (ACOG) Undervaluation: The Market Is Pricing the Wrong Year Price: \\\~$6.00 Market cap: \\\~$130M Cash: \\\~$73M Enterprise value: $57M FDA Approved Alzheimer's Drug ZUNVEYL (9th drug to …

Alpha Cognition (ACOG: Nasdaq) Undervaluation Thesis -A $6 Stock (EV: $57M) That's Being Valued on Trailing Revs Instead of 2026 Reality Alpha Cognition (ACOG) Undervaluation: The Market Is Pricing the Wrong Year Price: \\\~$6.00 Market cap: \\\~$130M Cash: \\\~$73M Enterprise value: $57M FDA Approved Alzheimer's Drug ZUNVEYL (9th drug to …